Importance Long-acting injectable antipsychotics (LAIs) can potentially reduce
hospitalization risk by enhancing medication adherence but are rarely considered for early …

Aim Results from clinical trials support the use of oral antipsychotics for treatment of early or
first‐episode psychosis in patients with schizophrenia. This paper will review literature on …

Objective: To document the acceptability of treatment with long-acting injectable (LAI)
antipsychotic medication to early-phase schizophrenia patients as demonstrated by …

Compared with oral antipsychotics (OAPs), long-acting injectable antipsychotics (LAIs)
should improve medication adherence and reduce relapses in schizophrenia. However …

Objective: It is generally believed that after the first episode of schizophrenia, the risk of
relapse decreases with time in patients who are stabilized. Many treatment guidelines …

Introduction Prevention of relapse is a major challenge in schizophrenia, a disease
characterized by poor adherence to antipsychotic medication leading to multiple …

BACKGROUND: Antipsychotic medications are a central component of effective treatment
for schizophrenia, but nonadherence is a significant problem for the majority of patients …

Medication nonadherence in schizophrenia can have serious implications including
relapses and hospitalization. Long-acting injectable (LAI) antipsychotics require fewer …

Background Among schizophrenia patients relapsed on an oral antipsychotic (AP), this
study compared the impact of switching to atypical AP long-acting injectable therapy (LAT) …

Until relatively recently, long-acting injectable (LAI) formulations were only available for first-
generation antipsychotics and their utilization decreased as use of oral second-generation …